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Abstracts
 
OBJECTIVES:
 
 To stimulate debate on the willingness of
purchasers to fund interventions with varying impact on
life years gained (LYG) and quality of life.
METHODS: The authors’ hypothesis is that, for two
health-care interventions (HCIs) with equal cost per qual-
ity adjusted life year (QALY) ratios, purchasers favour
the intervention that extends life, rather than the one that
improves quality of life.
RESULT: The list describes a conceptual framework for
assessing the relative benefit of a HCI according to its
ability to extend life or improve quality of life. Low LYG,
Low QALY  Limited Intervention, Low LYG, High
QALY  Lifestyle Intervention, High LYG, Low QALY 
Life Extending Intervention, High LYG, High QALY 
Optimal Intervention. If this hypothesis is correct it
means that there is a need for a new measure of health
gain that distinguishes between ‘life extending’ and ‘qual-
ity of life improving’ HCIs and that builds on the QALY.
As an interim step, the authors suggest that both QALYs
and LYG values be cited in future studies and a new ratio
be adopted. New Ratio  QALY  LYG As this ratio
tends towards 0, the HCI tends towards a ‘life extending
intervention.’ As this ratio tends towards infinity, the
HCI tends towards a ‘lifestyle intervention.’ Factors other
than QALYs and LYG influence purchasers and results
of this new ratio should be interpreted with caution.
CONCLUSIONS: LYG and QALYs are widely recog-
nized and respected measures of HCI effect and are fre-
quently used in economic evaluation. Viewed in isolation
the measures do not inform purchasers as to the nature of
the HCI effect, and a ratio of the two would help im-
prove this understanding. The authors would welcome
feedback from purchasers as to how useful this new mea-
sure would be in informing health-care resource alloca-
tion decisions.
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OBJECTIVE: The reliability of a computer program to au-
tomatically scan and interpret data from manually-coded,
data-collection forms was evaluated in a resource-utilization
study of patients undergoing total knee-replacement surgery
and receiving low molecular-weight heparin therapy to pre-
vent deep vein thrombosis.
METHODS: Detailed in-patient data was extracted by
technicians via manual chart review and recorded on 13-
page forms. To expedite the analysis, Teleform 6.2 was
used to design the data-collection form and later, to auto-
matically scan and interpret each form returned.
RESULTS: The reliability of this technology was evalu-
ated for the first 100 eligible-patient forms received. Of
all field entries, Teleform automatically processed 89.9%
without an operator verification prompt. The remaining
ambiguous fields were viewed and edited on screen by an
operator. Data for each completed form was then for-
warded to an output data set. The output data set records
were compared against screen images of the original data
forms to determine the reliability of this process. An aver-
age of 183 field entries was recorded for each patient and
scanned by Teleform. 99.0% of the fields in the output
data set matched completely with the handwritten field
entries on the original forms. This reliability varied
slightly with the type of field analyzed. Check box, date,
numeric, and alphanumeric fields had reliability scores of
100.0%, 99.8%, 99.6% and 96.5%, respectively.
CONCLUSION: This program shows promise for orga-
nizations that routinely collect information on hard-copy
forms, though the required learning curve and cost ham-
pers its value for the occasional user or for small projects.
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OBJECTIVE:
 
 The National Institute for Clinical Excel-
lence (NICE) is a UK government-funded body that re-
sponds to requests for guidance from the Department for
Health on the use of selected new and established tech-
nologies in the NHS in England and Wales. In March
2001 NICE published its “guidance to manufacturers”
for these submissions, essentially economic evaluation
guidelines for publicly-funded health-care services includ-
ing, but not restricted to, pharmaceuticals. This presenta-
tion analyzes the extent to which the NICE guidelines use
economics to contribute to the goals articulated in the
NICE documentation for health maximization and to re-
move unfairness in the availability of technologies under
a fixed NHS resource constraint.
METHODS: We analyze from an economics perspective
the problems giving rise to the need for guidelines, the
theoretical basis of the guidelines, and the implications of
the guidelines for health maximization and rectifying un-
fair availability.
RESULTS: The NICE guidelines fail to reflect important
economic aspects concerned with constrained health
maximization and unfair availability. The guidelines can-
not be expected to lead to maximization of health gain
from NHS resources and hence may fail to serve the
needs of NHS decision-makers. In addition, use of the
guidelines could result in continued expansion of expen-
ditures as predicted by economic analysis.
CONCLUSIONS: The guidelines aim to provide system-
wide solutions, based on standardized methods, to what
are essentially locally-based, non-standardized problems.
Although guidelines might be helpful in dealing with
matters of administrative process, the need for or ability
of such an approach to accommodate the intellectual
